# FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema

> **NCT01315990** · PHASE4 · UNKNOWN · sponsor: **Dr. Carl Schimanski** · enrollment: 165 (estimated)

## Conditions studied

- Colorectal Cancer Metastatic

## Interventions

- **DRUG:** FOLFIRI + Cetuximab

## Key facts

- **NCT ID:** NCT01315990
- **Lead sponsor:** Dr. Carl Schimanski
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-01
- **Primary completion:** 2015-03
- **Final completion:** 2018-03
- **Target enrollment:** 165 (ESTIMATED)
- **Last updated:** 2013-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01315990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01315990, "FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT01315990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*